#AS­CO21: Watch out Bris­tol My­ers, J&J is back at AS­CO with some com­pet­i­tive BC­MA CAR-T da­ta

Bris­tol My­ers Squibb and blue­bird beat John­son & John­son to mar­ket back in March with their BC­MA CAR-T drug, Abec­ma, for heav­i­ly pre-treat­ed mul­ti­ple myelo­ma pa­tients. But watch out: J&J and their part­ners at Leg­end Biotech are now head­ing to AS­CO with up­dat­ed da­ta that could give Abec­ma a run for its mon­ey.

A longer-term fol­low-up from the Phase Ib por­tion of a Phase Ib/II tri­al shows that all pa­tients re­spond­ed to J&J’s JNJ-4528, 86% of whom achieved a strin­gent com­plete re­sponse at a me­di­an of 11.5 months. In Phase II, there was a 95% over­all re­sponse rate as of the Feb­ru­ary da­ta cut­off, with a 75% strin­gent com­plete re­sponse, the com­pa­ny said Fri­day.  The da­ta are part of the pack­age J&J is sub­mit­ting in rolling ap­pli­ca­tions for ap­provals in Eu­rope and the US.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER